Download citation file:
From the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; University of California, Los Angeles, Los Angeles, California; and Centers for Disease Control and Prevention, Atlanta, Georgia.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Grant Support: By the National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases R37049381 and National Institute of Allergy and Infectious Diseases R0141935, R0154980, and U01067854) and the University of North Carolina Center for AIDS Research (P30050410). Dr. Gay has been supported by a Centers for Disease Control and Prevention Association of Teachers of Preventive Medicine Fellowship and National Institutes of Health Training Grant (T32AI07151).
Potential Financial Conflicts of Interest: Consultancies: A.D.M. Kashuba (Roche, Abbott, Boehringer Ingelheim, GlaxoSmithKline); Honoraria: A.D.M. Kashuba (Bristol-Myers Squibb, Pfizer Inc.); Grants received: A.D.M. Kashuba (Gilead Sciences, Abbott, Pfizer Inc.).
Requests for Single Reprints: Myron S. Cohen, MD, University of North Carolina at Chapel Hill, CB# 7030, 130 Mason Farm Road, 2115 Bioinformatics Building, Chapel Hill, NC 27599-7030; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Cohen: University of North Carolina at Chapel Hill, CB# 7030, 130 Mason Farm Road, 2115 Bioinformatics Building, Chapel Hill, NC 27599-7030.
Dr. Gay: University of North Carolina at Chapel Hill, CB# 7030, 130 Mason Farm Road, 2112 Bioinformatics Building, Chapel Hill, NC 27599-7030.
Dr. Kashuba: School of Pharmacy, 3318 Kerr Hall, CB# 7360, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360.
Dr. Blower: Semel Institute of Neuroscience & Human Behavior, David Geffen School of Medicine at University of California, Los Angeles, 1100 Glendon Avenue, PH2, Westwood, CA 90024.
Dr. Paxton: Epidemiology Branch, Centers for Disease Control and Prevention, 1600 Clifton Road, MS E-45, Atlanta, GA 30333.
Antiretroviral therapy (ART) has prolonged and improved the lives of persons infected with HIV. Theoretically, it can also be used to prevent the transmission of HIV. The pharmacology of ART in the male and female genital tract can be expected to affect the success of the intervention, and ART agents differ considerably in their ability to concentrate in genital tract secretions. Emergency ART is considered to be the standard of care after occupational exposures to fluids or tissues infected with HIV. More recently, ART for prophylaxis after nonoccupational HIV exposures has been widely used and most countries have developed specific guidelines for its implementation. However, developing clinical trials to prove the efficacy of ART postexposure prophylaxis has not been possible. Experiments with rhesus macaques suggest that therapy must be offered as soon as possible after exposure (within 72 hours) and must be continued for 28 days. Additional nonhuman primate experiments have demonstrated protection from HIV infection with ART preexposure prophylaxis, and several clinical trials are under way to evaluate the safety and efficacy of this approach. The degree to which ART offered to infected persons reduces infectiousness is of considerable public health importance, but the question has not been sufficiently answered. This article provides a review of the data on the use of ART to prevent the sexual transmission of HIV and identify challenges to improving and clarifying this approach.
Data from references 31 and 33 to 41. 3TC = lamivudine; ABC = abacavir; APV = amprenavir; ATV = atazanavir; d4T = stavudine; ddI = didanosine; DLV = delavirdine; EFV = efavirenz; ENF = enfuvirtide; FI = fusion inhibitor; FTC = emtricitabine; IDV = indinavir; LPV = lopinavir; ND = not detected; NFV = nelfinavir; NNRTI = nonnucleoside reverse transcriptase inhibitor; N(t)RTI = nucleotide reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RTV = ritonavir; SQV = saquinavir; TDF = tenofovir; ZDV = zidovudine.
Substantial HIV exposure is the exposure to blood, genital secretions, breast milk, or any body fluid visibly contaminated with blood of a person known to be infected with HIV. Negligible-risk exposure is exposure to urine, nasal secretions, saliva, sweat, or tears not visibly contaminated with blood, regardless of known or suspected HIV status of the source. Adapted from reference 77.
The y-axis summarizes the peak of viral burden in semen in some patients with acute HIV. The numbers in parentheses suggest the probability of HIV transmission per episode of penile–vaginal intercourse. The shaded areas suggest the potential benefits of an intervention that lowers peak and steady-state viral burden. Reprinted with permission from reference 97. Copyright 2005 by Journal of Infectious Diseases.
Please read the other comments before posting. Contributors must reveal any conflict
Comments are moderated and will appear on the site at the discretion of The American
College of Physicians editorial staff. Please be sure your email address is
updated in your account, otherwise the American College of Physicians will not be
able to contact you about your comment.
Anyone can submit a comment any time after publication, but only those submitted within 4 weeks of an article’s publication will be considered for print publication. One month after publication, editors review all posted comments and select some for publication in the Letters section of the print version of Annals. (Not peer reviewed)
Authors: No more than 5
Text: Word Limit 400 (excludes references), 5 references, no figures or tables
* = Required Field
Disclosure of Any Conflicts of Interest*
(applies to the past 5 years and foreseeable future) Indicate any potential conflicts
of interest of each author below, including specific financial interests and relationships
and affiliations relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honoraria, speakers
bureau, stock ownership or options, expert testimony, royalties, donation of medical
equipment, or patents filed, received, or pending). If all authors have none, check
"No potential conflicts or relevant financial interests" in the box below. Please
also indicate any funding received in support of this work. The information will
be posted with your response.
The In the Clinic® slide sets are owned and copyrighted by the American College
of Physicians (ACP). All text, graphics, trademarks, and other intellectual property
incorporated into the slide sets remain the sole and exclusive property of the ACP.
The slide sets may be used only by the person who downloads or purchases them and
only for the purpose of presenting them during not-for-profit educational activities.
Users may incorporate the entire slide set or selected individual slides into their
own teaching presentations but may not alter the content of the slides in any way
or remove the ACP copyright notice. Users may make print copies for use as hand-outs
for the audience the user is personally addressing but may not otherwise reproduce
or distribute the slides by any means or media, including but not limited to sending
them as e-mail attachments, posting them on Internet or Intranet sites, publishing
them in meeting proceedings, or making them available for sale or distribution in
any unauthorized form, without the express written permission of the ACP. Unauthorized
use of the In the Clinic slide sets will constitute copyright infringement.
to gain full access to the content and tools.
Learn more about subscription options